Interferon beta-1a
Regulatory milestones approvals, filings & regulatory actions · 10 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (4) | US (FDA) | REBIF | — | 2003-05-02 – 2020-05-26 | fda.gov ↗ |
| Label expansions (4) | US (FDA) | AVONEX | — | 2002-11-12 – 2020-03-27 | fda.gov ↗ |
| Approved | EU (EMA) | Avonex | — | 1997-03-13 | europa.eu ↗ |
| Approved | US (FDA) | AVONEX | — | 1996-05-17 | fda.gov ↗ |
Trials 61 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 110 trials | ||||||
| Phase 1 | NCT04183491 | Feb 2020 → Jan 2021 | — | Food and Drug Administration (FDA) | Completed | No outcome recorded |
| Phase 1 | NCT03614715 | Nov 2017 → Feb 2019 | — | Cinnagen | Completed | No outcome recorded |
| Phase 1 | NCT02364986 | Jan 2015 → Jan 2017 | relapsing-remitting multiple sclerosis | PD Dr. Marcus Müller | Unknown | No outcome recorded |
| Phase 1 | NCT02269930 | Oct → Dec 2014 | multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT01766024 | Feb → Jun 2013 | — | Biocad | Completed | No outcome recorded |
| Phase 1 | NCT01416207 | Aug → Oct 2011 | — | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT01119677 | May → Oct 2010 | — | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT02515695 | May → Jul 2005 | relapsing-remitting multiple sclerosis | Centre Hospitalier Universitaire Vaudois | Completed | No outcome recorded |
| Phase 1 | NCT00097318 | Nov 2004 → Apr 2011 | cerebral infarction | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 1 | NCT01863069 | Jan → Oct 2001 | multiple sclerosis | Trio Medicines Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05936229 | Apr 2025 → Oct 2027 | B-cell acute lymphoblastic leukemia, mantle cell lymphoma | Fred Hutchinson Cancer Center | Withdrawn | No outcome recorded |
| Phase 215 trials | ||||||
| Phase 2 | NCT06999603 | Sep 2025 → Apr 2027 expected | viral pneumonia | Synairgen Research Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06510426 | Jul 2024 → Jul 2025 overdue | West-Nile encephalitis | Tel-Aviv Sourasky Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04521400 | Aug → Sep 2020 | COVID-19 | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT04343768 | Apr 2020 | COVID-19 | Shahid Beheshti University of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT03119701 | Feb 2017 → Sep 2019 | multiple organ dysfunction syndrome | Faron Pharmaceuticals Ltd | Terminated | No outcome recorded |
| Phase 2 | NCT02491684 | Jul 2015 → Nov 2016 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT01126177 | Mar 2010 → Oct 2011 | asthma | Synairgen Research Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT00616434 | May 2008 → Mar 2010 | ulcerative colitis | Biogen | Completed | No outcome recorded |
| Phase 2 | NCT01075763 | Nov 2004 → May 2008 | Alzheimer disease | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 2 | NCT00099489 | Feb 2004 → Feb 2006 | chronic inflammatory demyelinating polyradiculoneuropathy | Biogen | Completed | No outcome recorded |
| Phase 2 | NCT00912860 | Jan 2003 → Dec 2004 | multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 2 | NCT00048347 | Oct 2002 → Jun 2008 | ulcerative colitis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00303381 | Dec 2001 → Jan 2003 | ulcerative colitis | EMD Serono | Completed | No outcome recorded |
| Phase 2 | NCT00304252 | Nov 2001 → Sep 2003 | Crohn disease | EMD Serono | Terminated | No outcome recorded |
| Phase 2 | NCT00001785 | Sep 1998 → Sep 2004 | spinal cord disorder, tropical spastic paraparesis | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04518410 | Aug 2020 → Apr 2022 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 313 trials | ||||||
| Phase 3 | NCT04492475 | Aug → Dec 2020 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT04315948 | Mar 2020 → Jul 2022 | COVID-19 | French National Institute of Health and Medical Research | Completed | No outcome recorded |
| Phase 3 | NCT04032158 | Aug 2019 → Apr 2020 | relapsing-remitting multiple sclerosis | EMD Serono Research & Development Institute, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT05242133 | Dec 2017 → Apr 2022 | relapsing-remitting multiple sclerosis | Cinnagen | Completed | No outcome recorded |
| Phase 3 | NCT02735707 | Apr 2016 → Feb 2026 overdue | pneumonia | UMC Utrecht | Recruiting | No outcome recorded |
| Phase 3 | NCT02622724 | Dec 2015 → May 2018 | adult acute respiratory distress syndrome | Faron Pharmaceuticals Ltd | Terminated | No outcome recorded |
| Phase 3 | NCT02937285 | Dec 2010 → May 2020 | multiple sclerosis | Rennes University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01181115 | Apr 2010 → Oct 2011 | multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 3 | NCT00828204 | Jan 2009 → Jul 2010 | multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 3 | NCT00784836 | Oct 2008 → Feb 2009 | multiple sclerosis | Biogen | Terminated | No outcome recorded |
| Phase 3 | NCT00287079 | Oct 2005 → Nov 2008 | — | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 3 | NCT00110396 | Jan 2005 → Apr 2007 | multiple sclerosis | EMD Serono | Completed | No outcome recorded |
| Phase 3 | NCT00249860 | Sep 2002 → Aug 2005 | chronic hepatitis C virus infection | EMD Serono | Completed | No outcome recorded |
| Phase 419 trials | ||||||
| Phase 4 | NCT04350671 | Apr 2020 | COVID-19 | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 4 | NCT02254304 | Dec 2014 → Aug 2016 | multiple sclerosis | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 4 | NCT02117050 | Jun 2014 → Apr 2015 | multiple sclerosis | EMD Serono | Terminated | No outcome recorded |
| Phase 4 | NCT02064816 | May 2014 → Apr 2016 | relapsing-remitting multiple sclerosis | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 4 | NCT01216072 | Aug 2010 → Aug 2012 | multiple sclerosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00771043 | Nov 2008 → Aug 2009 | relapsing-remitting multiple sclerosis | Biogen | Withdrawn | No outcome recorded |
| Phase 4 | NCT00574041 | Jun 2007 → Feb 2008 | relapsing-remitting multiple sclerosis | Biogen | Terminated | No outcome recorded |
| Phase 4 | NCT01142466 | Dec 2005 → Dec 2009 | relapsing-remitting multiple sclerosis | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 4 | NCT00101959 | Nov 2004 → ? | relapsing-remitting multiple sclerosis | EMD Serono | Withdrawn | No outcome recorded |
| Phase 4 | NCT00493077 | May 2004 → May 2006 | multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 4 | NCT00078338 | Feb 2004 → Nov 2006 | relapsing-remitting multiple sclerosis | EMD Serono | Completed | No outcome recorded |
| Phase 4 | NCT00493116 | Oct 2003 → Dec 2009 | relapsing-remitting multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 4 | NCT00492466 | Mar 2003 → Aug 2006 | relapsing-remitting multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 4 | NCT00913666 | Nov 2002 → Nov 2004 | multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 4 | NCT00037115 | May → Dec 2002 | multiple sclerosis, myelitis, neuritis, optic neuritis | MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute | Withdrawn | No outcome recorded |
| Phase 4 | NCT00037102 | Jul 2001 → Dec 2003 | multiple sclerosis | MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute | Completed | No outcome recorded |
| Phase 4 | NCT00179478 | Feb 2001 → Mar 2009 | cerebelloparenchymal disorder, multiple sclerosis, optic neuritis, transverse myelitis | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00534261 | Nov 1999 → Feb 2004 | relapsing-remitting multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 4 | NCT00915460 | Sep 1999 → Jun 2003 | multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT05024006 | Apr 2020 → Apr 2021 | COVID-19 | University of the Philippines | Completed | No outcome recorded |
| — | NCT00137176 | Oct 2004 → Oct 2007 | multiple sclerosis | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
Also used as a comparator or background therapy in 68 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02359877 Comparator | Jul 2014 → Oct 2015 | — | Biocad | Completed | No outcome recorded |
| Phase 1 | NCT01074593 Comparator | Jan → Mar 2011 | — | Azidus Brasil | Completed | No outcome recorded |
| Phase 1 | NCT02517788 Comparator | May → Jul 2006 | relapsing-remitting multiple sclerosis | Centre Hospitalier Universitaire Vaudois | Completed | No outcome recorded |
| Phase 220 trials | ||||||
| Phase 2 | NCT06019130 Background | Jan 2023 → Jan 2026 overdue | nasopharyngeal carcinoma | German Society for Pediatric Oncology and Hematology GPOH gGmbH | Recruiting | No outcome recorded |
| Phase 2 | NCT05298670 Background | Feb 2022 → Feb 2023 | multiple sclerosis | German University in Cairo | Unknown | No outcome recorded |
| Phase 2 | NCT04385095 Comparator | Mar 2020 → Feb 2021 | COVID-19 | Synairgen Research Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT03570359 Comparator | Jan 2018 → May 2020 | chronic obstructive pulmonary disease | Synairgen Research Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01864148 Background | Aug 2013 → Dec 2015 | multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 2 | NCT01403376 Comparator | Sep 2011 → Jan 2012 | multiple sclerosis | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT01285401 Background | Feb 2011 → Apr 2015 | relapsing-remitting multiple sclerosis | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 2 | NCT01071083 Comparator | Mar 2010 → Nov 2011 | relapsing-remitting multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 2 | NCT01198132 Background | Nov 2009 → Mar 2015 | multiple sclerosis | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 2 | NCT00676715 Comparator | Jul 2008 → Mar 2012 | relapsing-remitting multiple sclerosis | Genentech, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00811395 Background | Oct 2007 → Apr 2010 | multiple sclerosis | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT00489489 Background | May 2007 → Jun 2009 | multiple sclerosis | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT00436826 Background | Nov 2006 → Sep 2011 | multiple sclerosis | EMD Serono Research & Development Institute, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00501943 Comparator | Jul 2006 → Oct 2012 | multiple sclerosis | University of California, San Francisco | Completed | No outcome recorded |
| Phase 2 | NCT00273364 Comparator | Nov 2005 → Jan 2017 | multiple sclerosis | Northwestern University | Completed | No outcome recorded |
| Phase 2 | NCT00217295 Background | Apr 2004 → Dec 2007 | multiple sclerosis | Multiple Sclerosis Institute | Unknown | No outcome recorded |
| Phase 2 | NCT00616187 Comparator | Oct 2003 → Jun 2007 | relapsing-remitting multiple sclerosis | Charite University, Berlin, Germany | Completed | No outcome recorded |
| Phase 2 | NCT00050778 Comparator | Dec 2002 → Sep 2007 | relapsing-remitting multiple sclerosis | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT00151801 Background | May 2002 → Dec 2008 | multiple sclerosis | S. Andrea Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01714089 Comparator | — | relapsing-remitting multiple sclerosis | Revalesio Corporation | Withdrawn | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT02744222 Comparator | Aug 2017 → Nov 2018 | relapsing-remitting multiple sclerosis | Biocad | Completed | No outcome recorded |
| Phase 2/3 | NCT02727907 Comparator | Feb 2015 → Nov 2016 | multiple sclerosis | Biocad | Completed | No outcome recorded |
| Phase 326 trials | ||||||
| Phase 3 | NCT06663189 Comparator | Jan 2025 → Jan 2027 expected | relapsing-remitting multiple sclerosis | University Hospital, Strasbourg, France | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT04647669 Comparator | Jun → Nov 2021 | COVID-19 | The University of The West Indies | Unknown | No outcome recorded |
| Phase 3 | NCT04732949 Comparator | Jan → Dec 2021 | COVID-19 | Synairgen Research Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03958877 Comparator | Oct 2019 → May 2027 expected | relapsing-remitting multiple sclerosis | Biogen | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04032171 Comparator | Sep 2019 → May 2020 | relapsing-remitting multiple sclerosis | EMD Serono Research & Development Institute, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT02294058 Comparator | Dec 2014 → Dec 2016 | multiple sclerosis | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT02283853 Comparator | Aug 2014 → Jul 2025 | relapsing-remitting multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 3 | NCT01975298 Comparator | Jan → Mar 2014 | relapsing-remitting multiple sclerosis | Teva Branded Pharmaceutical Products R&D, Inc. | Withdrawn | No outcome recorded |
| Phase 3 | NCT02047734 Comparator | Dec 2013 → Mar 2017 | relapsing-remitting multiple sclerosis | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT01892722 Comparator | Jul 2013 → Jul 2017 overdue | multiple sclerosis | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01412333 Comparator | Sep 2011 → May 2015 | multiple sclerosis | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01247324 Comparator | Aug 2011 → Apr 2015 | multiple sclerosis | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01064401 Comparator | May 2010 → Mar 2014 | relapsing-remitting multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 3 | NCT01058005 Comparator | Mar 2010 → Apr 2012 | relapsing-remitting multiple sclerosis | Biogen | Terminated | No outcome recorded |
| Phase 3 | NCT00883337 Comparator | Apr 2009 → Sep 2011 | relapsing-remitting multiple sclerosis | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00725985 Background | Dec 2008 → Jul 2011 | multiple sclerosis | EMD Serono Research & Development Institute, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00605215 Comparator | Apr 2008 → Jun 2011 | multiple sclerosis | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00548405 Comparator | Oct 2007 → Sep 2011 | relapsing-remitting multiple sclerosis | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT00530348 Comparator | Aug 2007 → Apr 2011 | relapsing-remitting multiple sclerosis | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT00619307 Comparator | Jul 2007 → Apr 2008 | multiple sclerosis | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 3 | NCT00472797 Comparator | Apr 2007 → Feb 2009 | multiple sclerosis | EMD Serono | Completed | No outcome recorded |
| Phase 3 | NCT00441103 Comparator | Dec 2006 → Nov 2008 | relapsing-remitting multiple sclerosis | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 3 | NCT00340834 Comparator | May 2006 → Jul 2011 | relapsing-remitting multiple sclerosis | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00915577 Background | Aug 2005 → Apr 2006 | multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 3 | NCT00211887 Comparator | Jan 2005 → Apr 2012 | relapsing-remitting multiple sclerosis | Fred Lublin | Completed | No outcome recorded |
| Phase 3 | NCT00292266 Comparator | Nov 1999 → Jun 2002 | relapsing-remitting multiple sclerosis | EMD Serono | Completed | No outcome recorded |
| Phase 416 trials | ||||||
| Phase 4 | NCT04350684 Background | Apr 2020 | COVID-19 | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 4 | NCT03177083 Comparator | Jan 2017 → Oct 2020 | relapsing-remitting multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 4 | NCT02234869 Comparator | Oct 2014 → Feb 2017 | multiple sclerosis | Biogen | Withdrawn | No outcome recorded |
| Phase 4 | NCT01791244 Background | Feb 2013 → Feb 2016 | relapsing-remitting multiple sclerosis | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 4 | NCT01623596 Comparator | Jun 2012 → Jul 2015 | relapsing-remitting multiple sclerosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01534182 Comparator | Jan 2012 → Jun 2013 | relapsing-remitting multiple sclerosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01317004 Comparator | May 2011 → Jun 2014 | relapsing-remitting multiple sclerosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01085318 Comparator | Jun 2010 → Feb 2012 | multiple sclerosis | EMD Serono | Completed | No outcome recorded |
| Phase 4 | NCT00317941 Comparator | Mar 2006 → Apr 2008 | relapsing-remitting multiple sclerosis | Bayer | Completed | No outcome recorded |
| Phase 4 | NCT00492765 Background | Feb 2006 → Apr 2010 | multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 4 | NCT01201343 Background | Jan 2005 → Jul 2010 | relapsing-remitting multiple sclerosis | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 4 | NCT00146068 Background | Sep 2004 → Dec 2007 | multiple sclerosis | University of North Carolina | Completed | No outcome recorded |
| Phase 4 | NCT00202995 Comparator | Jul 2004 → Oct 2007 | relapsing-remitting multiple sclerosis | Teva Branded Pharmaceutical Products R&D, Inc. | Terminated | No outcome recorded |
| Phase 4 | NCT00246324 Background | Dec 2003 → Aug 2009 | multiple sclerosis | Louisiana State University Health Sciences Center Shreveport | Completed | No outcome recorded |
| Phase 4 | NCT00206648 Comparator | Mar 2003 → Oct 2005 | relapsing-remitting multiple sclerosis | Bayer | Completed | No outcome recorded |
| Phase 4 | NCT00168766 Background | Jan 2003 → Nov 2008 | relapsing-remitting multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01641120 Background | May 2012 → Feb 2014 | multiple sclerosis | Trinity Health Of New England | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-10-28 | Novartis Pharmaceuticals | Novartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya® vs. interferon beta-1a novartis.com ↗ |
Evidence & citations 31 cited values
Every value below carries the sentence it was read from. 145 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | interferon beta 1 a | “Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex (interferon beta 1a), Betaseron (interferon beta 1b), Copaxone (glatiramer...” NCT00273364 ↗94“The purpose of this study is to determine the safety, tolerability and efficacy of a combination therapy interferon beta-1a(Avonex) plus simvastatin (Zocor) vs. interferon...” NCT00146068 ↗ “This is a Phase 4, interventional, multicenter study of subcutaneous Rebif® (interferon beta-1a) using RebiSmart™ device to assess effectiveness and adherence of treatment in...” NCT02254304 ↗ “The participant will receive weekly intramuscular treatment with AVONEX® (interferon beta 1-a) and a one-time high dose intravenous methotrexate with Leucovorin rescue, along...” NCT00037115 ↗ “RNF (Rebif New Formulation, Merck Serono International S.A., Geneva, Switzerland), a formulation of interferon-beta1a (IFN-beta1a) without human- or animal-derived components,...” PMID 17692727 ↗ Jun 2007 “Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial.” PMID 33189161 ↗ Nov 2020 “s.c. interferon beta-1a injected three times per week (Rebif®) have demonstrated efficacy in relapsing-remitting multiple sclerosis” PMID 27060836 ↗ May 2016 “This study will evaluate the safety and effectiveness of the drug interferon-beta1a (AVONEX) in treating ulcerative colitis” NCT00048347 ↗ “Interferon beta-1a (\[IFNB-1a\] Rebif) 44 mcg (12 MIU) three times per week by subcutaneous injection using Rebiject II” NCT00317941 ↗ “Natalizumab (TYSABRI®) or Interferon beta-1a (AVONEX®) treatments initiated at the time of acute optic neuritis (AON)” NCT00771043 ↗ “Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis.” PMID 20200197 ↗ Mar 2010 “Immediate initiation of therapy with Interferon Beta-1a (AVONEX) after a first attack of multiple sclerosis (MS)” NCT00179478 ↗ “selected Standard MS DMT such as Interferon beta-1b or Interferon beta-1a or Glatiramer acetate for 6 months.” NCT01216072 ↗ “Ongoing treatment with intramuscular interferon beta-1a plus oral doxycycline, 100 mg daily, for 4 months.” PMID 18071030 ↗ Dec 2007 “morning administration of interferon beta 1a (Rebif®) leads to a lower severity of flu-like symptoms” NCT02064816 ↗ “Weekly dose of 30 mcg Interferon beta-1a (Avonex) administered by intramuscular injection.” NCT01714089 ↗ “current Rebif (subcutaneously injected interferon beta-1a, 44 mcg three-times-weekly)” NCT00619307 ↗ “versus Interferon-beta-1a (Avonex®), once a week intramuscularly” NCT04032158 ↗ “Interferon beta 1a or interferon beta 1b or Glatiramer Acetate” NCT01317004 ↗ “Interferon Beta 1a in Hospitalized COVID-19 Patients” NCT04350671 ↗ “Interferon beta 1 a (Rebiff ® 44mcg or Avonex ®)” NCT05298670 ↗ “human interferon beta 1a - Rebif New Formulation” NCT00472797 ↗ “intramuscular interferon beta-1a (30 μg weekly)” PMID 21742556 ↗ Aug 2011 “intravenous interferon-beta-1a (FP-1201) works” NCT05936229 ↗ “Interferon beta 1a, oral doxycycline” NCT00246324 ↗ “BCD-033 (interferon beta 1a)” NCT02727907 ↗ “Avonex (Interferon Beta-1a)” NCT01181115 ↗ “Avonex (Interferon beta 1a)” NCT00501943 ↗ “BG9418 (interferon beta-1a)” NCT00828204 ↗ “Drug: Interferon beta-1a” NCT01075763 ↗ |
| Known as | AVONEX | “Participants received IFN-beta therapy (Rebif® new formulation \[RNF\] 44 microgram \[mcg\] three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or...” NCT00436826 ↗32“Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex (interferon beta 1a), Betaseron (interferon beta 1b), Copaxone (glatiramer...” NCT00273364 ↗ “The purpose of this study is to determine the safety, tolerability and efficacy of a combination therapy interferon beta-1a(Avonex) plus simvastatin (Zocor) vs. interferon...” NCT00146068 ↗ “The participant will receive weekly intramuscular treatment with AVONEX® (interferon beta 1-a) and a one-time high dose intravenous methotrexate with Leucovorin rescue, along...” NCT00037115 ↗ “The purpose of this study is to determine whether AVONEX (Interferon Beta-1a), when compared to placebo, reduces the total dose of IVIg that is administered after Visit 5 and...” NCT00099489 ↗ “Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM)” NCT00001785 ↗ “Immediate initiation of therapy with Interferon Beta-1a (AVONEX) after a first attack of multiple sclerosis (MS)” NCT00179478 ↗ “Participants will receive Avonex (interferon beta type 1a) starting at a dose of 7.5 μg on Day 1” NCT03958877 ↗ “Weekly dose of 30 mcg Interferon beta-1a (Avonex) administered by intramuscular injection.” NCT01714089 ↗ “Interferon Beta preparation (Exctavia, Betaseron, Rebif, Avonex)” NCT01623596 ↗ “Interferon beta 1 a (Rebiff ® 44mcg or Avonex ®)” NCT05298670 ↗ “Avonex 30 µg IM once per week” NCT00206648 ↗ “Interferon beta-1a (AVONEX®)” NCT00534261 ↗ “Interferon beta-1a (Avonex)” NCT00915460 ↗ |
| Known as | AZD9412 | “OBJECTIVE: To evaluate the efficacy of on-demand inhaled IFN-β1a (AZD9412) to prevent severe asthma exacerbations following symptomatic URTI.” PMID 33091192 ↗ Nov 2020 |
| Known as | BCD-033 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02727907 ↗ |
| Known as | BG9418 | “BG9418 (Interferon beta-1a)” NCT00616434 ↗ |
| Known as | FP-12-lyo | “FP-12-lyo 10 µg (Interferon Beta-1a) will be administered once daily as an intravenous bolus injection for 6 days.” NCT03119701 ↗ |
| Known as | FP-1201 | “intravenous interferon-beta-1a (FP-1201) works” NCT05936229 ↗ |
| Known as | IFN | “determine whether combined use of interferon β-1a (IFN) 30 μg intramuscularly weekly and glatiramer acetate (GA) 20 mg daily is more efficacious than either agent alone in...” PMID 23424159 ↗ Mar 2013 |
| Known as | IFN Beta 1a | “The primary objective of this initiative is to assess the effectiveness of subcutaneous (sc) interferon (IFN) beta - 1a, (Rebif®), versus No Treatment in delaying the...” NCT00287079 ↗5“Mortality remains high after emergency open surgery for a ruptured abdominal aortic aneurysm (RAAA). The aim of the present study was to assess, if intravenous (IV) Interferon...” PMID 35115574 ↗ Feb 2022 “patients with steroid-induced clinical remissions of CD were randomized 1:1:1:1 to subcutaneous IFN beta-1a: 66 mcg three times weekly (tiw), 44 mcg tiw, 44 mcg twice weekly...” PMID 19302707 ↗ Mar 2009 “RNF (Rebif New Formulation, Merck Serono International S.A., Geneva, Switzerland), a formulation of interferon-beta1a (IFN-beta1a) without human- or animal-derived components,...” PMID 17692727 ↗ Jun 2007 “Recombinant human interferon beta-1a (IFN-Beta1a) is an FDA approved treatment for patients with relapsing remitting multiple sclerosis” NCT00097318 ↗ “sc IFN Beta 1a (Rebif®) Administered in the Morning” NCT02064816 ↗ |
| Known as | IFN-ß-1a | “IFN-ß-1a is supplied as a sterile solution containing no preservative available in a prefilled syringe.” NCT04315948 ↗1“IFN-ß-1a 44 Mcg Tiw SC (Rebif®)” NCT00101959 ↗ |
| Known as | IFN-β | “Interferon-β (IFN-β), glatiramer acetate, dimethyl fumarate, teriflunomide or diroximel fumarate” NCT06663189 ↗1“Interferon-β [IFN-β]” NCT00811395 ↗ |
| Known as | IFN-β-1 | “Influenza vaccine in participants treated with a stable dose of Interferon-β-1 (IFN-β-1) for at least 6 months” NCT01403376 ↗ |
| Known as | IFNB-1a | “The primary purpose is to determine the changes in gene expression induced by IFNb-1a (Rebif) and atorvastatin (Lipitor) combination therapy in patients with an isolated...” NCT00137176 ↗2“Interferon beta-1a (\[IFNB-1a\] Rebif) 44 mcg (12 MIU) three times per week by subcutaneous injection using Rebiject II” NCT00317941 ↗ “Interferon beta-1a (IFNB-1a), a FDA approved therapy for relapsing-remitting (RR) MS has several mechanisms of action.” NCT00146068 ↗ |
| Known as | IFNβ-1a | “fingolimod administered for up to 2 years significantly reduced the annualised relapse rate (ARR) and rate of new/newly enlarged T2 (n/neT2) lesions compared with interferon (IFN) β-1a.” PMID 31467033 ↗ Aug 201910“Women with relapsing-remitting (RR) MS were randomly assigned (1:1:1) to receive subcutaneous IFN-β-1a (Rebif®, Merck Serono, Geneva, Switzerland) 44 mcg three times a week (tiw)” PMID 27995531 ↗ Feb 2017 “Eligible patients with RRMS treated with SC interferon-β-1a (IFN-β-1a) 44 μg 3 times weekly and serum 25(OH)D levels <150 nmol/L were included.” PMID 31594857 ↗ Oct 2019 “OBJECTIVE: To compare the efficacy, safety, and tolerability of DMF vs intramuscular interferon β-1a (IFNβ-1a) in POMS.” PMID 36169959 ↗ Sep 2022 “Treatment protocol would include 3 subcutaneous injections of IFN-β1a (Rebif), at a dose of 44mcg, given every 48h.” NCT06510426 ↗ “adjuvant therapy to interferon beta 1a (IFNβ-1a) in relapsing-remitting multiple sclerosis (RRMS) patients.” PMID 38070031 ↗ Dec 2023 “interferon beta-1a (IFN β-1a; Avonex®) in reducing the rate of clinical relapses” NCT02047734 ↗ “SNG001, IFN-β1a solution for inhalation” NCT01126177 ↗ “IFN-β-1a 22 µg s.c. 3 times weekly” NCT00616187 ↗ “High dose IFN-β1a (Recigen)” NCT04521400 ↗ “IFN β-1a (Avonex)” NCT02283853 ↗ |
| Known as | Interferon beta type 1a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03958877 ↗ |
| Known as | Interferon ß-1a | “Interferon ß-1a will be administered intravenously at the dose of 10 μg once daily for 6 days if oxygen dependent or subcutaneously at 44 ug Day 1, Day 3, and Day 6” NCT04647669 ↗ |
| Known as | Interferon-β | “Interferon-β (IFN-β), glatiramer acetate, dimethyl fumarate, teriflunomide or diroximel fumarate” NCT06663189 ↗ |
| Known as | Interferon-β 1a | “The intervention drug given will be interferon β1a. Treatment protocol would include 3 subcutaneous injections of IFN-β1a (Rebif), at a dose of 44mcg, given every 48h.” NCT06510426 ↗6“Interferon-β 1a + Lopinavir / Ritonavir + Single Dose of Hydroxychloroquine” NCT04350671 ↗ “Interferon β1a(daily injection for 6 days)” NCT04647669 ↗ |
| Known as | Interferon-β-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01403376 ↗ |
| Known as | Rebif | “Participants received IFN-beta therapy (Rebif® new formulation \[RNF\] 44 microgram \[mcg\] three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or...” NCT00436826 ↗26“This is a Phase 4, interventional, multicenter study of subcutaneous Rebif® (interferon beta-1a) using RebiSmart™ device to assess effectiveness and adherence of treatment in...” NCT02254304 ↗ “Women with relapsing-remitting (RR) MS were randomly assigned (1:1:1) to receive subcutaneous IFN-β-1a (Rebif®, Merck Serono, Geneva, Switzerland) 44 mcg three times a week (tiw)” PMID 27995531 ↗ Feb 2017 “Treatment protocol would include 3 subcutaneous injections of IFN-β1a (Rebif), at a dose of 44mcg, given every 48h.” NCT06510426 ↗ “morning administration of interferon beta 1a (Rebif®) leads to a lower severity of flu-like symptoms” NCT02064816 ↗ “Safety and Efficacy of Treatment With Interferon Beta-1a Rebif® in Patients With Crohn's Disease” NCT00304252 ↗ “current Rebif (subcutaneously injected interferon beta-1a, 44 mcg three-times-weekly)” NCT00619307 ↗ “Interferon Beta preparation (Exctavia, Betaseron, Rebif, Avonex)” NCT01623596 ↗ “Rebif or Betaseron/Betaferon” NCT02234869 ↗ “Rebif® (Interferon Beta-1a)” NCT00472797 ↗ |
| Known as | Rebif (R) | “Rebif (R) is a purified 166 amino acid human interferon beta glycoprotein with an amino acid sequence identical to natural fibroblast derived human interferon beta. Each 0.5 mL...” NCT04492475 ↗ |
| Known as | Rebif New Formulation | “human interferon beta 1a - Rebif New Formulation” NCT00472797 ↗1“Rebif® New Formulation (IFN-beta-1a, RNF)” NCT00441103 ↗ |
| Known as | Rebif(Registered Trademark) | “The purpose of this study is to investigate the safety of IFN-Beta1a (Rebif(Registered Trademark)) in patients with acute ischemic stroke.” NCT00097318 ↗ |
| Known as | Rebiff | “Interferon beta 1 a (Rebiff ® 44mcg or Avonex ®)” NCT05298670 ↗ |
| Known as | Recigen | “High dose IFN-β1a (Recigen)” NCT04521400 ↗1“Interferon-β 1a (Recigen)” PMID 32493468 ↗ Jun 2020 |
| Known as | Recombinant Human Interferon Beta-1a | “A study to assess effectiveness and safety of a drug FP-1201-lyo (Recombinant Human Interferon Beta-1a) in the Prevention of Multi-Organ Failure on patients after Open Surgery...” NCT03119701 ↗ |
| Known as | RNF | “received Rebif® new formulation (RNF) subcutaneously at a dose of 44 microgram (mcg) three times a week for up to 96 weeks.” NCT00725985 ↗1“Rebif® New Formulation (IFN-beta-1a, RNF)” NCT00441103 ↗ |
| Known as | SNG001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06999603 ↗ |
| Action | Inhibit | “Studies have shown that interferon-beta may block the activity of these cytokines.” NCT00048347 ↗ |
| Modality | Protein / enzyme biologic | “Human interferon is a small protein released from different kinds of cells in the body.” NCT00001785 ↗ |
| Route | Intramuscular | “weekly intramuscular treatment with AVONEX® (interferon beta 1-a)” NCT00037102 ↗ |